{ "schemaVersion": "deck-intelligence.v1", "id": "019de070-699f-77f8-bbbb-b770da56fde3", "slug": "068a25e0403b2abb3acbdc102f073cd6", "title": "BioNTech | Results Presentation Deck | 25 slides", "subtitle": "BioNTech · 2020-11", "author": "BioNTech", "date": "2020-11-01 00:00:00", "pageCount": 25, "kind": "deck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de070-699f-77f8-bbbb-b770da56fde3", "slug": "068a25e0403b2abb3acbdc102f073cd6", "title": "BioNTech | Results Presentation Deck | 25 slides", "rawTitle": "BioNTech | Results Presentation Deck | 25 slides", "authorId": "biontech", "authorName": "BioNTech", "authorDisplay": "BioNTech", "kind": { "slug": "deck", "label": "Deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2020-11__biontech__results__068a25e0.pdf", "sourceUrl": "https://www.slidebook.io/company/biontech/presentation/068a25e0403b2abb3acbdc102f073cd6/", "sourceDate": "2020-11-10 00:00:00", "presentationDate": "2020-11-01 00:00:00", "ingestedAt": "2026-04-30 22:09:16.80745+00", "status": "ready", "pageCount": 25, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2020-11__biontech__results__068a25e0", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Results Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 25, "pagesIndexed": 25, "pagesWithImages": 25, "pagesWithMetadata": 25, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 100, "chartCount": 10, "metricSlides": 0, "toolMatches": 7, "documentToolMatches": 0, "frameworkMatches": 5, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "evidence": "The deck follows a structure similar to Sequoia Pitch, with sections on problem, solution, market size, product, and financials", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:11:06.710732+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Problem", "beatId": "909e9f48-661f-4023-bec4-80e16f7c12be", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "COVID-19 vaccine development timeline", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 23, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 22, "name": "Financials", "beatId": "f2f3d40a-5c41-471a-9e39-5bfb9ea0f9b3", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "Third Quarter 2020 Financial Results", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 4, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 4, "name": "Key Takeaways", "beatId": "cbfce4db-5b7b-4c8f-806a-40f9ab62d11e", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": null, "evidence": "Q3 2020 Highlights", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 24, "name": "Key Takeaways", "beatId": "4c5aeb71-ccb0-4701-b1e8-62fb462dcea8", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": null, "evidence": "Positioned for transformative 2021", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 6, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "61305adf-2089-4bb0-85ef-0e7a43625a5c", "evidence": "COVID-19 vaccine development timeline", "position": 0, "objective": "Why now is the right time for BioNTech's pipeline", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:11:06.90937+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 24, "from": 24, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "c54aca5a-7c93-4977-aaba-f709a659d8b1", "evidence": "Positioned for transformative 2021", "position": 1, "objective": "Positioning for transformative 2021", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:11:06.943768+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "0ef54230-a66b-45f8-967d-ba824a4b49d1", "evidence": "Corporate update and financial results", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:31:20.333245+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e8802553-2fcd-4e5e-b1e4-8ed7fad83003", "evidence": "list/bullet: BNT 162 COVID-19 Vaccine Program: Achieved Success in First Interim Analysis from Phase 3 Study; No serious adverse events; Rolling submissions ongoing; On track for EUA; Initiated trials in Japan/China; Acq", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:31:20.51011+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "5ef328b3-3652-44c6-b3b7-937f0fe029f3", "evidence": "The slide uses a bar-stacked chart and a table to present data, which suggests an effort to eliminate chartjunk and present information clearly.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 23:31:22.224945+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Small Multiples", "slug": "small-multiples", "status": "active", "bestFor": null, "canonId": "019dd956-b32d-7586-b368-baa1dd388ed4", "version": 1, "bodyDocId": null, "description": "Repeating similar charts for comparison across categories or time", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "1d7f331e-e1ea-4280-a23e-d17c8aede5d3", "evidence": "The slide presents multiple box charts (A, B, C, D) that compare different variables, which is a characteristic of small multiples.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 23:31:22.297068+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "05a1e16e-ef32-40db-8c18-aab89093ec6e", "evidence": "The slide features a waterfall chart titled 'Best percent change from baseline in tumor size', which directly instantiates the waterfall chart tool.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:31:22.36671+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "0e83255d-cf56-4ebe-9379-e758ac307d7c", "evidence": "The slide uses a bar chart and a line chart to present data, which may indicate consideration of chart selection principles.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-16 23:31:22.437035+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4a83e23a-71d9-49e3-93eb-c1aad7fce5e7", "evidence": "Profit and Loss table showing revenues, costs, expenses, and net loss for Q3 and YTD 2020 vs 2019.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:31:51.600384+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "084d6d56-e00d-4dba-aab9-e14fd2b4c0f6", "evidence": "Standard agenda slide format", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:57:32.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "list-presentation" }, { "matchId": "86ea4de9-b137-40c6-b5d9-1b2af1070a58", "evidence": "Chronological sequence of events presented on a horizontal axis.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:57:33.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" }, { "matchId": "4e8b12f5-7149-43e0-8565-c43f61dfceac", "evidence": "Geographic visualization of clinical trial status", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "map-spatial" }, { "matchId": "bae407fb-3371-4ca4-9fb8-6be2c234149a", "evidence": "The table uses horizontal bars to represent clinical trial phases over time/stage.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "gantt-chart" }, { "matchId": "a7c3526c-4aa9-4aed-b8fb-eb6c9e84429f", "evidence": "The slide uses a simple bulleted list to structure the agenda.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:57:34.147+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "list-presentation" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/OA-3ybOysQ-Ia1IL5vkX70gbLGRzeK2lgNbyflqQp5k/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNjhhMjVlMDQwM2IyYWJiM2FjYmRjMTAyZjA3M2NkNi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 34, "componentCount": 5, "textChars": 81, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:31.766+00", "seconds": 2.656, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/1", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-1", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.13, "x": 0.838, "y": 0.93 }, "kind": "image", "text": "BIONTECH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f3afdc8-b2ca-4afe-84f1-efd0ab7073fc", "parentComponentId": null }, { "bbox": { "h": 0.66, "w": 0.53, "x": 0.47, "y": 0.17 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b314f9a-880b-48c1-9c8e-616d1d0095fd", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.117, "y": 0.718 }, "kind": "paragraph", "text": "November 10, 2020", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "00d6f915-4556-441b-a083-765debd42f2f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.22, "x": 0.117, "y": 0.472 }, "kind": "paragraph", "text": "Corporate update and financial results", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33835837-3431-4531-951d-c0e3b19d68d4", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.315, "x": 0.117, "y": 0.337 }, "kind": "title", "text": "Third Quarter 2020", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1f4748e-a2a4-4b2f-b829-e67a06650371", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "0ef54230-a66b-45f8-967d-ba824a4b49d1", "evidence": "Corporate update and financial results", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:31:20.333245+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/Fv7DqLBOd4xYpoqxc7X9ca_z3GjJYcX8auwkNmi5l1Q/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNjhhMjVlMDQwM2IyYWJiM2FjYmRjMTAyZjA3M2NkNi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/qOFic0wtJeuGzidbjhiRh5JRwG1uEWE4HzpywBjt7Bs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNjhhMjVlMDQwM2IyYWJiM2FjYmRjMTAyZjA3M2NkNi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/rk77wSJ8ZyE2UeGv-ChAIOURS8GdC8DlBZuf40qgvb8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wNjhhMjVlMDQwM2IyYWJiM2FjYmRjMTAyZjA3M2NkNi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 21, "componentCount": 2, "textChars": 288, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:31.974+00", "seconds": 2.201, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/2", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-2", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.715, "w": 0.914, "x": 0.043, "y": 0.188 }, "kind": "disclaimer", "text": "Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects... The mRNA vaccines and other product candidates discussed in this slide presentation are investigational products being developed by BioNTech.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f708c731-0363-4338-810d-f7d5f5b2c6e4", "parentComponentId": null }, { "bbox": { "h": 0.038, "w": 0.376, "x": 0.043, "y": 0.098 }, "kind": "title", "text": "Forward-looking statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:31.974+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cdc8da6-2aea-4697-8020-ce1d4c68eb5f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 107, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:32.118+00", "seconds": 2.209, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/3", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-3", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.45, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "Q3 Highlights\nBNT162 (COVID-19 vaccine program)\nOncology Pipeline Update\nFinancial Update and Outlook", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:32.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82571d46-de70-44b3-8693-0d3f6d291a28", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:32.118+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "60c5458c-8aac-4eec-98fa-e39164fec8c5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 5, "textChars": 726, "nDataPoints": 4, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.181+00", "seconds": 3.032, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/4", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-4", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.92, "x": 0.04, "y": 0.195 }, "kind": "list", "text": "BNT 162 COVID-19 Vaccine Program: Achieved Success in First Interim Analysis from Phase 3 Study; No serious adverse events; Rolling submissions ongoing; On track for EUA; Initiated trials in Japan/China; Acquired GMP facility; Commercial planning underway.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f9493ab-1440-44b2-9547-d79e3876c736", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.92, "x": 0.04, "y": 0.76 }, "kind": "list", "text": "Financial Update and Outlook: Closed $1.2B financing; $0.8B net cash receipts; $1.2B cash position.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a2f30ca-d8a5-469e-996f-f21c6ca964ae", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.92, "x": 0.04, "y": 0.55 }, "kind": "list", "text": "Oncology Pipeline: Promising early Phase 1 data for BNT311; Early Phase 1 data for BNT131 and BNT114; IND approval for iNeST (BNT122); First patient dosed in BNT411.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0510f5d-6db8-4864-88ba-328bd10bc1a4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.73, "x": 0.09, "y": 0.935 }, "kind": "source-note", "text": "Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f52a185b-e04e-4e0a-bc58-c55b5b6614ed", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.265, "x": 0.038, "y": 0.095 }, "kind": "title", "text": "Q3 2020 Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.181+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed00d7ff-e75b-4c39-8a36-aaef172d9e4c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e8802553-2fcd-4e5e-b1e4-8ed7fad83003", "evidence": "list/bullet: BNT 162 COVID-19 Vaccine Program: Achieved Success in First Interim Analysis from Phase 3 Study; No serious adverse events; Rolling submissions ongoing; On track for EUA; Initiated trials in Japan/China; Acq", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:31:20.51011+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 4, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 4, "name": "Key Takeaways", "beatId": "cbfce4db-5b7b-4c8f-806a-40f9ab62d11e", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": null, "evidence": "Q3 2020 Highlights", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 5, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 107, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:32.11+00", "seconds": 1.842, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/5", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-5", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.333, "w": 0.431, "x": 0.042, "y": 0.278 }, "kind": "list", "text": "Q3 Highlights\nBNT162 (COVID-19 vaccine program)\nOncology Pipeline Update\nFinancial Update and Outlook", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:32.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2724b828-2cfa-4361-ba77-ab6c30510d9e", "parentComponentId": null }, { "bbox": { "h": 0.048, "w": 0.144, "x": 0.053, "y": 0.105 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:32.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb087341-01d3-4967-b168-1713e01b8648", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "084d6d56-e00d-4dba-aab9-e14fd2b4c0f6", "evidence": "Standard agenda slide format", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:57:32.11+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "list-presentation" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "evidence", "title": "The slide uses a horizontal timeline with icons and callouts to mark key regulatory and clinical trial milestones.", "function": "illustrate_case", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 543, "nDataPoints": 12, "notes": "The slide uses a horizontal timeline with icons and callouts to mark key regulatory and clinical trial milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.853+00", "seconds": 3.332, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/6", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-6", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.115, "w": 0.235, "x": 0.744, "y": 0.18 }, "kind": "callout", "text": "Primary Efficacy Endpoint: To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 in participants with (and without) evidence of infection before vaccination", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64b0ea2d-1b39-426e-9730-75313bcf7716", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.92, "x": 0.04, "y": 0.45 }, "kind": "diagram", "text": "Horizontal timeline with milestones from Jan 2020 to Nov 2020", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77a07fea-5c01-4429-bcfb-48cfe19d2017", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.92, "x": 0.04, "y": 0.65 }, "kind": "list", "text": "SARS-CoV-2 Genetic Sequence (Jan 12, 2020); Program Initiation (Jan 27, 2020); Collaborations (Mar 16-17, 2020); Phase 1/2a (Apr-May 2020); Fast Track (July 13, 2020); Pivotal Phase 2b/3 (July 27, 2020); Rolling Submissions (Oct 2020); Interim analysis (Nov 9, 2020)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18287ae5-632f-4c28-a4ac-726655e2ca9c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "COVID-19 vaccine development timeline", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36985c79-0958-47a5-aac7-ed0bc0c8912a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "86ea4de9-b137-40c6-b5d9-1b2af1070a58", "evidence": "Chronological sequence of events presented on a horizontal axis.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:57:33.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 6, "name": "Problem", "beatId": "909e9f48-661f-4023-bec4-80e16f7c12be", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "COVID-19 vaccine development timeline", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 6, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "61305adf-2089-4bb0-85ef-0e7a43625a5c", "evidence": "COVID-19 vaccine development timeline", "position": 0, "objective": "Why now is the right time for BioNTech's pipeline", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:11:06.90937+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "evidence", "title": "Includes flags of participating countries, trial flow diagram, and demographic breakdown.", "function": "illustrate_case", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 517, "nDataPoints": 7, "notes": "Includes flags of participating countries, trial flow diagram, and demographic breakdown.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:38.717+00", "seconds": 8.098, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/7", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-7", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.65, "x": 0.08, "y": 0.16 }, "kind": "diagram", "text": "Trial flow diagram showing participant enrollment, vaccination schedule, and active surveillance.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:38.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b06abbad-c298-495d-9c3d-d4875f7d4184", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.42, "x": 0.55, "y": 0.03 }, "kind": "image", "text": "Country flags", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:38.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73642665-df20-40a1-b3ca-d53d2c94ce0f", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.72, "x": 0.05, "y": 0.68 }, "kind": "list", "text": "Interim analysis of unblinded data by independent data monitoring committee on Nov 8, 2020: 94 disease cases accrued, >90% Vaccine Efficacy, Benign safety profile. Final efficacy analysis expected end of Nov 2020. Long-term monitoring for 2 years.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:38.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52095f6f-9d62-4440-b6ce-dc82e56d65a0", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.23, "x": 0.74, "y": 0.45 }, "kind": "table", "text": "Race/Ethnicity breakdown: Asian 5%, Black 10%, Hispanic/Latinx 26%, Native American 0.8%. Total enrolled 43,538, 38,955 received 2nd dose.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:38.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "120534df-d274-4792-beaa-2ec1033bda1e", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.32, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "BNT162b2 Phase 3 trial", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:38.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "342ff7b1-8c67-4ca7-a9c5-761d61a54873", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 8, "type": "appendix", "title": "The slide uses color-coding to distinguish between regions with ongoing trials (light green) and those with regulatory submissions on a rolling basis (dark gree", "function": "illustrate_case", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 5, "textChars": 259, "nDataPoints": 0, "notes": "The slide uses color-coding to distinguish between regions with ongoing trials (light green) and those with regulatory submissions on a rolling basis (dark green).", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.702+00", "seconds": 2.991, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/8", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-8", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.92, "x": 0.04, "y": 0.83 }, "kind": "callout", "text": "Regulatory submission on a rolling basis to EMA, MHRA (UK) and Health Canada initiated in October", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5ff6387-58c8-4ccd-93ae-95ad450c6bd5", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.85, "x": 0.07, "y": 0.18 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dbc71efd-6f03-4771-a848-87e205851a62", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.05, "y": 0.64 }, "kind": "legend", "text": "Regulatory submissions on a rolling basis; Ongoing trials", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "751022dc-2cbb-4144-a30e-9fe2dd956d89", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.1, "y": 0.94 }, "kind": "source-note", "text": "Phase 1/2 remains ongoing in U.S. and EU", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c961774-2cdb-4e56-922f-433d0c75ab02", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "BNT162: Global development program expanded to additional regions", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5cbbf931-704a-4f3a-9275-29ae9b8fd38b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4e8b12f5-7149-43e0-8565-c43f61dfceac", "evidence": "Geographic visualization of clinical trial status", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:57:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "map-spatial" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "analysis", "title": "The slide highlights significant supply commitments across multiple regions, with some financial and volume details withheld.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 390, "nDataPoints": 6, "notes": "The slide highlights significant supply commitments across multiple regions, with some financial and volume details withheld.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.785+00", "seconds": 2.921, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/9", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-9", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.38, "x": 0.04, "y": 0.375 }, "kind": "list", "text": "> 570 million doses committed* for 2020 and 2021 in 13 countries and the EU with an option to purchase an additional 600 million doses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a967ae14-a343-49e2-8f76-808d321f9320", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.38, "x": 0.04, "y": 0.565 }, "kind": "list", "text": "Additional commercial discussions ongoing with multiple countries and supranational organizations including COVAX", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2d0a9fd-9816-4d9b-ad86-8d2af445a8b2", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.925 }, "kind": "source-note", "text": "* Subject to clinical success and regulatory approval", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4fb1b54e-4646-4d38-8897-aa3d29eff767", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.53, "x": 0.43, "y": 0.185 }, "kind": "table", "text": "Commercial supply commitments table by region", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0af7485-f888-4827-a706-7cda3ea78c46", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.1 }, "kind": "title", "text": "BNT162: Global commercial supply commitments*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f069cd3e-78a9-4ac1-b9f9-bf21ef4e7f63", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "appendix", "title": "The slide outlines a cold-chain logistics process for a pharmaceutical product.", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 6, "textChars": 263, "nDataPoints": 6, "notes": "The slide outlines a cold-chain logistics process for a pharmaceutical product.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.49+00", "seconds": 2.574, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/10", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-10", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.25, "x": 0.37, "y": 0.4 }, "kind": "diagram", "text": "Distribution flow from manufacturing to point of care", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.49+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7317c6e-6e8b-4e02-91cf-cf4d131d6c75", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.92, "x": 0.04, "y": 0.185 }, "kind": "diagram", "text": "Packaging, Distribution, Storage at Point of Care", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.49+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1412708-6c2a-44b4-bc6a-eed14a21db36", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.13, "x": 0.11, "y": 0.35 }, "kind": "image", "text": "Thermal shipper packaging", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.49+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2cb203c-5711-4d27-9d71-9e819faf3841", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.28, "x": 0.69, "y": 0.3 }, "kind": "list", "text": "Thermal shipper, Ultralow Temperature Freezer, Refrigerator storage specs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.49+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "15a24e60-4f8b-4456-9518-ed354c294479", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.69, "y": 0.85 }, "kind": "paragraph", "text": "Stability testing of BNT162b2 ongoing", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.49+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8140e17a-fc65-4e5b-95a0-3a154ee3743e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "BNT162: Distribution model", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.49+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6bdc0427-7e50-40f8-b1c1-bda5491b2af7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 107, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.389+00", "seconds": 2.376, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/11", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-11", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.333, "w": 0.431, "x": 0.043, "y": 0.278 }, "kind": "list", "text": "Q3 Highlights\nBNT162 (COVID-19 vaccine program)\nOncology Pipeline Update\nFinancial Update and Outlook", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.389+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "972cf71e-492e-4288-9c49-0de3489afc6e", "parentComponentId": null }, { "bbox": { "h": 0.048, "w": 0.144, "x": 0.053, "y": 0.106 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.389+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae74785f-41d5-45f4-aeea-943b729c5644", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 12, "type": "setup", "title": "The slide uses a Gantt-style visualization for clinical trial phases.", "function": "present_solution", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 5, "textChars": 387, "nDataPoints": 11, "notes": "The slide uses a Gantt-style visualization for clinical trial phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.945+00", "seconds": 3.91, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/12", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-12", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.22, "x": 0.75, "y": 0.25 }, "kind": "callout", "text": "Clinical updates and trial status notes", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59d0d951-28cf-4f27-afc5-a671ee044b8e", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.2, "x": 0.45, "y": 0.25 }, "kind": "chart", "text": "Clinical trial phase bars", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "207acec2-d0f0-4f20-abcc-8d349464cefa", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.04, "y": 0.87 }, "kind": "source-note", "text": "1BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials. 2Checkpoint Inhibitor. 3Small Molecule Immunomodulators.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3096d1b3-53a3-48c7-8bb9-44e52c3fcf5b", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.67, "x": 0.04, "y": 0.215 }, "kind": "table", "text": "Drug class, Platform, Product Candidate, Indication, Pre-clinical, Phase 1, Phase 2, Rights/Collaborator", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b59a6da-6c34-413a-8c57-ea239e149fd3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "Oncology pipeline: Expanded to 11 product candidates in 12 clinical trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a6ab517-1ed6-4178-b8cb-534a8b663dcd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "bae407fb-3371-4ca4-9fb8-6be2c234149a", "evidence": "The table uses horizontal bars to represent clinical trial phases over time/stage.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:57:34.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 13, "type": "resolution", "title": "FIH = First in Human; PRT = Protein Replacement Therapy; 3 = We are eligible to receive worldwide licenses", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 4, "textChars": 371, "nDataPoints": 0, "notes": "FIH = First in Human; PRT = Protein Replacement Therapy; 3 = We are eligible to receive worldwide licenses", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.064+00", "seconds": 2.981, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/13", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-13", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.12, "x": 0.85, "y": 0.415 }, "kind": "callout", "text": "We expect to initiate multiple Phase 1 trials in 2021", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46e7aace-dde6-4448-95ad-10c0c7b9702c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.04, "y": 0.93 }, "kind": "source-note", "text": "1 FIH = First in Human; 2 PRT = Protein Replacement Therapy; 3 We are eligible to receive worldwide licenses", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "acb4b9f5-9d52-4e02-b4a6-41b6e7ad4724", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.8, "x": 0.04, "y": 0.18 }, "kind": "table", "text": "Pipeline table with columns: Drug class, Platform, Product Candidate, Indication (Targets), Rights Collaborator, Milestones", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6d02a19-0519-4898-8a21-06460353a9a2", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "We plan to initiate multiple FIH1 trials for our preclinical product candidates in 2021", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.064+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b32d018-627e-4521-992d-ba4a31a1eae4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 14, "type": "appendix", "title": "The slide illustrates the biological mechanism of a bispecific antibody targeting PD-L1 and 4-1BB.", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 3, "textChars": 525, "nDataPoints": 0, "notes": "The slide illustrates the biological mechanism of a bispecific antibody targeting PD-L1 and 4-1BB.", "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:33.433+00", "seconds": 2.347, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/14", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-14", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.92, "x": 0.04, "y": 0.205 }, "kind": "image", "text": "Mechanism of action diagram showing molecular interaction and cellular activity in lymph nodes and tumor microenvironment.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9842d13-4799-4e23-a240-34fca3cdbde1", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.04, "y": 0.75 }, "kind": "list", "text": "First-in-class, next generation checkpoint immunotherapy designed to enhance T cell and NK cell function through conditional 4-1BB co-stimulation while simultaneously blocking T cell axis. Enhances proliferation and cytokine production of activated T cells, activates immune cells in tumor-draining lymph nodes, and induces tumor regression in vivo", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18fc4552-b915-4bca-a8df-e8566d7376b1", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "BNT311: Next-generation bispecific antibody PD-L1x4-1BB", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:33.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6836b2ac-d680-49ca-a301-2cc266f3b95f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a staircase diagram to represent dose escalation and a list for expansion cohorts.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 588, "nDataPoints": 15, "notes": "The slide uses a staircase diagram to represent dose escalation and a list for expansion cohorts.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.955+00", "seconds": 3.751, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/15", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-15", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.42, "x": 0.07, "y": 0.45 }, "kind": "chart", "text": "Dose escalation steps from 25mg to 1200mg", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd4e3401-11f5-4ac8-b5c2-53c92ed1c24e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.26, "x": 0.04, "y": 0.215 }, "kind": "diagram", "text": "Phase 1 Dose Escalation N=61", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ebadb39-6abb-4882-a4ba-7181753cd5ef", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.31, "x": 0.65, "y": 0.21 }, "kind": "diagram", "text": "Phase 2a Dose Expansion N=Up to 40 per cohort", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58d24927-aac5-46c9-a4e8-4aa71f4220b6", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.31, "x": 0.65, "y": 0.37 }, "kind": "list", "text": "EC1: NSCLC ≤ 2-4L p. ICI; EC2: NSCLC ≤ 2-4L ICI n.; EC3: Urothelial Ca ≤ 2-4L p. ICI; EC4: Endometrial Ca ≤ 2-4L ICI n.; EC5: TNBC ≤ 2-4L CPI n./ p. ICI; EC6: SCCHN ≤ 2-4L CPI n./ p. ICI; EC7: Cervical Ca ≤ 2-4L ICI n.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fdbb3c2a-b29b-4809-8334-6a9b0ed77d87", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.04, "y": 0.85 }, "kind": "paragraph", "text": "BNT311/GEN1046: intravenous flat dose every 3 weeks until disease progression or unacceptable toxicity", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "541ac40e-221b-42ee-9634-56c41fbe8b0e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.65, "y": 0.83 }, "kind": "source-note", "text": "p. ICI = post immune checkpoint inhibition; CPI n. = check point inhibitor naive", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "28ac7dcb-911e-4ebc-8ec8-24c1153fce14", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "BNT311: Safety Trial in Patients With Malignant Solid Tumors (NCT03917381)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e9e078e-8991-4fac-b155-1939ccb5b514", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "analysis", "title": "Data presented in a table format showing age, gender, cancer type, and prior treatment history.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 3, "textChars": 676, "nDataPoints": 14, "notes": "Data presented in a table format showing age, gender, cancer type, and prior treatment history.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:39.199+00", "seconds": 7.836, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/16", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-16", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.4, "x": 0.55, "y": 0.28 }, "kind": "list", "text": "A total of 61 patients were enrolled in the dose escalation part of the trial. Patients were heavily pretreated, receiving a median (range) of 3 (1–11) treatments; nearly 40% had received prior PD-(L)1 treatment", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:39.199+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1af5fafe-f9ed-43b3-9827-019a70bd1cd8", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.5, "x": 0.04, "y": 0.228 }, "kind": "table", "text": "Dose Escalation Cohort, All patients N=61, Median age, years (range) 59 (23, 79), Age group, n (%) <65 years 44 (72.1), ≥65 years 17 (27.9), Female, n (%) 28 (45.9), Cancer type, a n (%) Colorectal cancer 12 (19.7), Ovarian cancer 9 (14.8), Pancreatic cancer 6 (9.8), NSCLC 6 (9.8), Other 28 (45.9), Median number of prior regimens, (range) 3 (1–11), Prior treatment with PD-(L)1 inhibitor, n (%) 23 (37.7)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:39.199+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25a6fd43-670f-4978-9e38-d382d4affd5b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "BNT311: Phase 1 / 2a - Dose Escalation Patient Demographics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:39.199+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "895d3918-43db-4605-9267-659e88afd6f2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 17, "type": "resolution", "title": "The chart uses a broken axis between 50 and 100.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 362, "nDataPoints": 24, "notes": "The chart uses a broken axis between 50 and 100.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:36.367+00", "seconds": 4.995, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/17", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-17", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.55, "x": 0.04, "y": 0.225 }, "kind": "chart", "text": "TEAEs occurring in ≥10% of patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:36.367+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7db77421-f2cd-427b-929d-a6077949dbf5", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.32, "x": 0.64, "y": 0.22 }, "kind": "list", "text": "The most common treatment-related adverse events were transaminase elevations, hypothyroidism and fatigue. Treatment-related transaminase elevations occurred in 26.2% of patients. There were no patients with Grade 4 transaminase. MTD has not been reached.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:36.367+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "08822fde-a568-4ad7-8c91-2e978f0a0d80", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.55, "x": 0.04, "y": 0.6 }, "kind": "table", "text": "TRAEs occurring in ≥10% of patients", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:36.367+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f570b54-5e4e-403e-abe5-07ee1a2a6316", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "BNT311: Phase 1 / 2a - Safety profile", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:36.367+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eb518cde-ba17-4003-9c57-178cf82a07dd", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "5ef328b3-3652-44c6-b3b7-937f0fe029f3", "evidence": "The slide uses a bar-stacked chart and a table to present data, which suggests an effort to eliminate chartjunk and present information clearly.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 23:31:22.224945+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 18, "type": "appendix", "title": "Data shows fold change from baseline for four different markers, comparing lower vs higher doses with statistical significance (p-values) indicated.", "function": "analyze_data", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 645, "nDataPoints": 8, "notes": "Data shows fold change from baseline for four different markers, comparing lower vs higher doses with statistical significance (p-values) indicated.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:35.215+00", "seconds": 3.605, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/18", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-18", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.15, "x": 0.68, "y": 0.25 }, "kind": "chart", "text": "D: Proliferating (Ki67+) effector memory CD8 T cells", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Box plot", "slug": "box", "status": "active", "canonId": "019de52d-020e-73d9-b4cf-5793a03e9b74", "version": 1, "description": null }, "framework": null }, "subkind": "box", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5931e308-add1-4361-8132-697e8adf2a44", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.15, "x": 0.13, "y": 0.25 }, "kind": "chart", "text": "A: IFN-y", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Box plot", "slug": "box", "status": "active", "canonId": "019de52d-020e-73d9-b4cf-5793a03e9b74", "version": 1, "description": null }, "framework": null }, "subkind": "box", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62ca6d41-9a6b-4638-b6b9-6134fb983cb7", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.15, "x": 0.5, "y": 0.25 }, "kind": "chart", "text": "C: Proliferating (Ki67+) CD8 T cells", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Box plot", "slug": "box", "status": "active", "canonId": "019de52d-020e-73d9-b4cf-5793a03e9b74", "version": 1, "description": null }, "framework": null }, "subkind": "box", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c569f229-c9d1-4dcb-b748-4ac59ca53305", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.15, "x": 0.31, "y": 0.25 }, "kind": "chart", "text": "B: IP-10", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Box plot", "slug": "box", "status": "active", "canonId": "019de52d-020e-73d9-b4cf-5793a03e9b74", "version": 1, "description": null }, "framework": null }, "subkind": "box", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfcb0160-c5a4-47c7-b634-42b64993a971", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.04, "y": 0.75 }, "kind": "list", "text": "Pharmacological activity was observed across a broad range of dose levels\nIncreased levels of peripheral IFN-g and IP-10, increased frequency of proliferating (Ki67+) total CD8 and effector memory CD8+ T cells were observed", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d847e3c3-047c-45ef-96df-b18e239a5be4", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.04, "y": 0.87 }, "kind": "source-note", "text": "Data extraction: June 26, 2020. Maximal fold-change from baseline measured during cycle 1. Lower doses correspond to dose levels ≤200 mg and higher doses correspond to dose levels ≥400 mg. Wilcoxon-Mann-Whitney test. IFN, interferon; IP-10, interferon-gamma-inducible protein 10.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f29f6f08-f939-40f9-b569-5fa891c1b998", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "BNT311: Phase 1 / 2a - Pharmacodynamics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad76d87e-0a33-460e-b9dd-2fc49cc3dd15", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Small Multiples", "slug": "small-multiples", "status": "active", "bestFor": null, "canonId": "019dd956-b32d-7586-b368-baa1dd388ed4", "version": 1, "bodyDocId": null, "description": "Repeating similar charts for comparison across categories or time", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "1d7f331e-e1ea-4280-a23e-d17c8aede5d3", "evidence": "The slide presents multiple box charts (A, B, C, D) that compare different variables, which is a characteristic of small multiples.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 23:31:22.297068+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 19, "type": "appendix", "title": "Waterfall plot showing clinical trial efficacy data.", "function": "analyze_data", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 4, "textChars": 703, "nDataPoints": 60, "notes": "Waterfall plot showing clinical trial efficacy data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.816+00", "seconds": 2.86, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/19", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-19", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.7 }, "kind": "callout", "text": "Disease control achieved in 65.6% of patients; four patients with PR. Includes 4 early partial responses in TNBC (1), ovarian cancer (1), and ICI-pre treated NSCLC (2) patients", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.816+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e09284d5-9e59-4064-8b79-bb31bf46e257", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.92, "x": 0.04, "y": 0.22 }, "kind": "chart", "text": "Best percent change from baseline in tumor size", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.816+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ae6e3f3-797a-4503-ab82-a5c7eafb8da2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.08, "y": 0.86 }, "kind": "source-note", "text": "Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients. aMinimum duration of response (5 weeks) per RECIST v1.1 not reached. bPR was not confirmed on a subsequent scan. NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.816+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c421267e-4f3e-49f1-85a3-5ff2b98e97bd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "BNT311: Phase 1 / 2a - Anti-tumor Activity: Dose escalation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.816+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40cbcf02-8f37-4ddf-bf48-33586731616a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "05a1e16e-ef32-40db-8c18-aab89093ec6e", "evidence": "The slide features a waterfall chart titled 'Best percent change from baseline in tumor size', which directly instantiates the waterfall chart tool.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:31:22.36671+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 20, "type": "appendix", "title": "Waterfall plot (A) and Spider plot (B) showing patient response data.", "function": "analyze_data", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 5, "textChars": 807, "nDataPoints": 24, "notes": "Waterfall plot (A) and Spider plot (B) showing patient response data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:35.047+00", "seconds": 3.002, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/20", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-20", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.45, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Best change from baseline in tumor size", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.047+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cb279d8-c50e-471f-9f3a-ce093c561244", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.52, "y": 0.25 }, "kind": "chart", "text": "Target lesion SoD change from baseline", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.047+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "830a8cbf-18c7-448b-b29c-824d60a43484", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.04, "y": 0.65 }, "kind": "paragraph", "text": "As of October 12, 2020, 24 patients were enrolled in expansion cohort 1, which includes patients with NSCLC with progression on or after ICI therapy. 12 patients had post-baseline scans; 6 patients were still on treatment with BNT311/GEN1046, 6 patients discontinued. Preliminary efficacy in 12 patients who could be objectively assessed showed two patients who achieved confirmed PR, one with unconfirmed PR, and four patients with SD.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.047+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d919d66-2d23-4398-abc4-aa9c72d595df", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.04, "y": 0.82 }, "kind": "source-note", "text": "Data cut-off: October 12, 2020. *Denotes patients with ongoing treatment. aPR was not confirmed by a subsequent scan. Includes all patients who had at least one post-baseline tumor assessment...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.047+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43f8c318-5f76-42a0-90e2-97d5572af3ef", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.8, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "BNT311: Phase 1 / 2a - Anti-tumor activity in immune checkpoint recurrent/refractory NSCLC Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.047+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "abe5cad1-8ed3-4dce-a41c-8628f1fe00c9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "0e83255d-cf56-4ebe-9379-e758ac307d7c", "evidence": "The slide uses a bar chart and a line chart to present data, which may indicate consideration of chart selection principles.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-16 23:31:22.437035+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 21, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 107, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.147+00", "seconds": 2.07, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/21", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-21", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.333, "w": 0.431, "x": 0.042, "y": 0.278 }, "kind": "list", "text": "Q3 Highlights\nBNT162 (COVID-19 vaccine program)\nOncology Pipeline Update\nFinancial Update and Outlook", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.147+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e182d53-a053-4067-ab45-146207b8232d", "parentComponentId": null }, { "bbox": { "h": 0.048, "w": 0.144, "x": 0.053, "y": 0.106 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.147+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1c84b2b-9c81-4e78-ab06-29c39e0c19b2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "a7c3526c-4aa9-4aed-b8fb-eb6c9e84429f", "evidence": "The slide uses a simple bulleted list to structure the agenda.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:57:34.147+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "list-presentation" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 22, "type": "analysis", "title": "Financial data presented in millions of Euros.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 35, "componentCount": 3, "textChars": 249, "nDataPoints": 44, "notes": "Financial data presented in millions of Euros.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.789+00", "seconds": 2.644, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/22", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-22", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.5, "x": 0.04, "y": 0.86 }, "kind": "source-note", "text": "1 Numbers have been rounded; numbers presented may not add up precisely to the totals", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a982a662-d784-4241-b663-dd1b707a2f82", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.92, "x": 0.04, "y": 0.22 }, "kind": "table", "text": "Profit and Loss table showing revenues, costs, expenses, and net loss for Q3 and YTD 2020 vs 2019.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "546bf54c-e5d7-4739-8ce6-ef7d83c6880c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "Third Quarter 2020 Financial Results (unaudited) – Profit and Loss", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.789+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8bf781ba-d367-486d-8d9f-4b2931dcf30b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4a83e23a-71d9-49e3-93eb-c1aad7fce5e7", "evidence": "Profit and Loss table showing revenues, costs, expenses, and net loss for Q3 and YTD 2020 vs 2019.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:31:51.600384+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 23, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 22, "name": "Financials", "beatId": "f2f3d40a-5c41-471a-9e39-5bfb9ea0f9b3", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "Third Quarter 2020 Financial Results", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 23, "type": "analysis", "title": "The slide uses a two-part structure to separate historical balance sheet data from forward-looking guidance.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 6, "textChars": 1244, "nDataPoints": 8, "notes": "The slide uses a two-part structure to separate historical balance sheet data from forward-looking guidance.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:35.683+00", "seconds": 3.362, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/23", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-23", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.75, "x": 0.22, "y": 0.4 }, "kind": "list", "text": "On August 28, 2020, BioNTech and a fund associated with Temasek closed a €100.0 million ($119.2 million) investment in a 4-year mandatory convertible note. Temasek and another accredited investor contributed a private investment of €123.9 million ($146.0 million) in ordinary shares.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.683+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "196f9a5f-7175-4318-937b-2faba16e12ed", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.75, "x": 0.22, "y": 0.22 }, "kind": "list", "text": "Cash and cash equivalents of €990.5 million ($1,159.7 million) as of September 30, 2020. On July 27, 2020, BioNTech closed an underwritten offering of 5,500,000 ADSs for gross proceeds of €435.0 million ($511.5 million).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.683+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "57d6f4eb-9805-46c5-8077-e4e365822965", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.75, "x": 0.22, "y": 0.56 }, "kind": "list", "text": "On September 15, 2020 BioNTech secured grant funding of up to €375.0 million ($439.1 million) in milestone-based funding from the BMBF to support and accelerate the BNT162 vaccine program execution.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.683+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "919af294-8995-470f-b347-4aa70b0dd681", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.75, "x": 0.22, "y": 0.77 }, "kind": "list", "text": "BioNTech expects net cash used in operating activities and for purchases of property, plant and equipment to be within the previously guided range of €450 million and €600 million for the full year 2020.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.683+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c58bb055-5f75-4732-a715-ba8ab2ef3301", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.21, "y": 0.9 }, "kind": "source-note", "text": "1 Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020. 2 German Federal Ministry of Education (Bundesministerium für Bildung und Forschung)", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.683+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f949be10-65bc-4b55-8fdc-751b71cd969b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.09 }, "kind": "title", "text": "Third Quarter 2020 Financial Results (unaudited) – Balance Sheet", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:35.683+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c5e5571-3fba-45fb-938e-86bbc57e119f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 23, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 22, "name": "Financials", "beatId": "f2f3d40a-5c41-471a-9e39-5bfb9ea0f9b3", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "Third Quarter 2020 Financial Results", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 24, "type": "resolution", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 35, "componentCount": 2, "textChars": 675, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.694+00", "seconds": 2.317, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/24", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-24", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.91, "x": 0.042, "y": 0.21 }, "kind": "list", "text": "Focused on executing ongoing BNT162 Phase 3 trial and regulatory submission processes globally\nCommercial preparation activities for manufacturing and global distribution progressing for BNT162 with partners Pfizer and Fosun\nAdvancing oncology pipeline towards multiple late-stage clinical trial initiations\nAdditional first-in-human trials of novel product candidates expected across proprietary platforms\nWell capitalized to deliver on key commercial, operational and pipeline milestones\nTransformational opportunity ahead to positively impact the world – and accelerate our long-term vision to build a next generation immunotherapy leader", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.694+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3bdb87fc-56aa-4e52-b375-f674ee6622b0", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.45, "x": 0.042, "y": 0.098 }, "kind": "title", "text": "Positioned for transformative 2021", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.694+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "15a227db-6c94-473b-9816-1e93570423e5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 24, "name": "Key Takeaways", "beatId": "4c5aeb71-ccb0-4701-b1e8-62fb462dcea8", "matchId": "155c39a3-ebe9-4e7c-97be-59ac7428d4e5", "beatType": null, "evidence": "Positioned for transformative 2021", "position": 4, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 24, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "c54aca5a-7c93-4977-aaba-f709a659d8b1", "evidence": "Positioned for transformative 2021", "position": 1, "objective": "Positioning for transformative 2021", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:11:06.943768+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "setup", "function": "transition", "rawType": "transition", "block": null, "metadata": { "slideType": "transition", "slideTypeCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-0693-7766-9f05-887f41f8e41e", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 11, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:57:34.388+00", "seconds": 1.869, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/25", "deck": "/decks/019de070-699f-77f8-bbbb-b770da56fde3", "deckAnchor": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-25", "deckJson": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.16, "x": 0.05, "y": 0.48 }, "kind": "image", "text": "BIONTECH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.388+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e03c330-b78a-4ff5-8da1-0a9e2ece9194", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.05, "y": 0.15 }, "kind": "title", "text": "Q&A", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:57:34.388+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0f4b019-8819-4732-b86f-e0985bd0cebf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 6, "to": 6, "label": "Problem", "description": "COVID-19 vaccine development timeline" }, { "from": 7, "to": 20, "label": "Solution", "description": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial" }, { "from": 22, "to": 23, "label": "Financials", "description": "Third Quarter 2020 Financial Results" }, { "from": 4, "to": 4, "label": "Key Takeaways", "description": "Q3 2020 Highlights" }, { "from": 24, "to": 24, "label": "Key Takeaways", "description": "Positioned for transformative 2021" } ], "loops": [ { "from": 6, "to": 6, "label": "Why Now", "description": "Why now is the right time for BioNTech's pipeline" }, { "from": 24, "to": 24, "label": "Quick Win Big Bet", "description": "Positioning for transformative 2021" } ] }